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Part one
Basal cell naevus syndrome
Basal cell naevus syndrome (BNCS), also known as Gorlin syndrome, is an autosomal dominant 
disorder, characterized by multiple basal cell carcinomas (BCCs), odontogenic keratocysts, 
cerebral calcifications and palmoplantar pits.1,2 The syndrome is associated with germline 
mutations in the Drosophila homolog of patched-1 (PTCH1) gene that encodes the PTCH1 protein. 
PTCH1 is part of the hedgehog (Hh) signalling pathway, which plays an important role in the 
regulation of cell growth and differentiation. BCNS belongs to the group of hereditary tumour 
syndromes, in which mutations in one or more genes predispose to the development of cancer. 
The development of sometimes hundreds of BCCs is a major problem in this group of patients.
Genetic basis of BCNS
In 1996 the patched-1 (PTCH1) gene (MIM#601309) was first reported as a candidate gene for 
BCNS. Two different heterozygous mutations in the PTCH1 gene were identified in two patients 
with BCNS.3 PTCH1 is the human homolog of the Drosophila patched-1 gene and is located on 
chromosome 9q22.3. With DNA sequencing analysis of the PTCH1 gene, mutation detection 
frequency ranges from 40% to 85% in individuals with typical findings of BCNS.4–8 In chapter 2 
we describe a new database containing all previously published and newly identified PTCH1 
mutations. We established a database for PTCH1 using the Leiden Open Variation Database 
(LOVD) version 3.0.9 The purpose of this database is to assemble molecular variants of the 
PTCH1 gene in a standardised format. The database provides an open collection for both 
clinicians and researchers containing published and unpublished PTCH1 mutations. To 
accomplish this, we listed the results from all blood samples sent to the two Diagnostic DNA 
Laboratories in the Netherlands for PTCH1 mutation analysis between 1999 and 2015. In 
chapter 3 we investigate whether there is a genotype-phenotype correlation in this population 
by collecting clinical symptoms from patients’ medical records. In this research, we only looked 
at the patients who carried a PTCH1 mutation in the blood. In the investigated Dutch cohort, 
we did not find a genotype-phenotype correlation based either on the location or on the type 
of PTCH1 mutation. Our findings are consistent with the results of previous studies and are in 
line with the phenotype variability within families found in this study.4,10–13 The presence of a 
germline mutation in SUFU increases the risk of developing medulloblastoma in childhood.6 
The presence of genetic variants (polymorphisms (SNPs), modifiers) that increase the risks of 
developing sporadic BCC, like MC1R and TERT-CLPTM1L, is associated with an earlier age of 
onset for BCCs in BCNS.14 The mutation detection percentage in our population is low (21%). 
Probably, relatively many patients with only minimal clinical symptoms of BCNS were tested. 
Another explanation can be that for many patients with clinical suspicion of BCNS, standard 
genetic tests are not yet suitable to detect the underlying genetic cause of the symptoms. 
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Postzygotic mosaicism in BCNS
In a substantial number of BCNS patients no PTCH1 mutation is found in DNA extracted from 
blood. It is known that genomic rearrangments in PTCH1 or deep intronic variants causing cryptic 
splicing cannot be detected with generally used genetic diagnostic tests.15 Also, mutations could 
be located in other genes involved in the Hh pathway (or yet unknown pathways), for example 
SUFU or PTCH2.6,16–18 Another explanation is the presence of genetic mosaicism. Low-grade 
mosaicism can be difficult or even impossible to detect in DNA extracted from blood. With 
standard techniques, e.g. Sanger sequencing, mutation loads under 5% are not detectable. 
Next generation sequencing (NGS) of target genes (i.e. PTCH1) in blood is more sensitive and 
has sufficient sequence read depth to not only reliably detect, but also quantify the degree of 
mosaicism19. Sometimes though, a mutation is only present in the skin and cannot be found in 
blood. When the presence of a mutation causes visible skin lesions, as in mosaic ichthyosis, the 
segmentally appearing skin disorder is an evident clue for the existence of segmental mosaicism 
caused by dominant mutations.20 Mosaic skin diseases may present different patterns as 
described in chapter 1. Lesions can for example follow the lines of Blaschko, in broad or narrow 
bands, or appear in a checkerboard pattern.21 In BCNS, but also in other hereditary tumour 
syndromes, skin with only one affected allele has a normal appearance. Only a second hit of 
the other allele, through loss-of-heterozygosity (LOH) or somatic gene mutation, initiates the 
development of a BCC. As the presence of a BCC is a marker for affected skin, genetic mosaicism 
in the patient can be demonstrated when different BCCs share the same PTCH1 mutation. In 
chapter 4 and 5 we described three patients with BCNS caused by PTCH1 mosaicism. Only in 
one patient there is a clear segmental distribution of skin lesions as they are limited to only one 
side of the body. This emphasizes the difficulty of recognizing a mosaic presentation of BCNS. 
To demonstrate a shared mutation in the different BCCs of these patients we used NGS in 
combination with a gene panel, consisting of a selection of genes participating in the Hh pathway 
including PTCH1, PTCH2, SUFU and SMO. Mosaic mutations in the latter has been described in 
Happle-Tinschert syndrome, that should be distinguished from mosaic BCNS22,23
Mosaic manifestations of other hereditary tumour syndromes have been described as well, 
for example neurofibromatosis type 1.24 In BCNS PTCH1 postzygotic mosaicism could actually 
be more common than previously assumed. It is plausible that patients do not always fulfil the 
diagnostic criteria of BCNS and may even present only with multiple BCCs at a young age. 
Of note, low-grade mosaicism can affect the gonadal cells as well. If this is the case, patients 
have a chance, although probably very small, to give birth to a child with a germline mutation 
of the disease. Unfortunately, the degree of involvement of different organ systems is difficult 
to predict. Therefore, surveillance programs and treatment of BCCs should have the same 
approach as in patients with a germline mutation. So, in patients suspected of having BCNS and 
a negative mutation analysis on blood, even with NGS techniques, it is worthwhile to search for 
a shared mutation in their BCCs. In case of mosaic disease, genetic counselling can be adjusted.
125
10
Summary, discussion, future perspectives and valorisation
Care pathways and patient customized health care
Currently, our department is developing an integrated care pathway for patients with BCNS. 
This project is a collaboration between different specialties: paediatrics, clinical genetics, 
maxillary surgery, (paediatric) neurology, ophthalmology, cardiology, gynaecology, psychology 
and medical oncology, with the dermatologist as the initiator of the project. The purpose of this 
plan is to standardize the health care for this group of patients based on best available evidence. 
The dermatologist has a central position in this care pathway, as the management of the multiple 
BCCs is a difficult and ongoing problem. Information about sun protective measures are very 
important in patients with BCNS, as individuals with a low tumour burden have significantly 
fewer UV signature somatic mutations.25 Our dermatology department offers specialized 
consultations for patients with BCNS. Treatment of multiple BCCs can be very complex and 
has a high psychological impact on patients. Different treatment modalities are available, and 
choices are preferably made combining evidence-based medicine with shared decision-making. 
Maintenance therapy with Hh pathway inhibitors, such as vismodegib, can be considered in 
selected patients as I will discuss in more detail in part two of this chapter.
Future perspectives
Insight into the genetic cause of BCNS is not only helpful to understand the pathogenesis of this 
syndrome. For the individual patient, it is just as important, because it allows us to diagnose the 
disease at an early age and to offer patients correct screening programs and adequate genetic 
counselling. 
Whole Exome Sequencing (WES) is increasingly used, especially in syndromes with no clearly 
defined candidate gene or in very heterogeneous diseases, because it enables the sequencing of 
all genes in one go. The method is however still costly and moreover it has a limited sequencing 
depth.19 In case of a high clinical suspicion of BCNS it is more efficient to look specifically at 
participants of the Hh pathway. We designed an NGS-based gene panel that includes PTCH1, 
PTCH2, SMO and SUFU. Its implementation in daily practice will provide a more effective, 
faster and less expensive diagnostic screening method for BCNS patients. Because of the 
higher sequencing depth, mosaic disease is more likely to be discovered. In patients with a 
high suspicion of BCNS in whom no PTCH1 mutation can be detected in blood with regular 
Sanger sequencing, it is worthwile to implement the gene panel, in order to analyze other genes 
involved in the Hh pathway, but also to reach a sequencing depth sufficient to detect low-grade 
mosaicism. To gain more information about the prevalence of mutations in other genes and the 
presence of mosaic disease in BCNS, it is of interest to look at the patients in our initial cohort 
that had no mutation in blood.
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Part two 
Treatment of locally advanced and metastasised
basal cell carcinoma with vismodegib
The development of Hh pathway inhibitors provided a new treatment option for patients with 
metastasized or locally advanced BCC ineligible for surgery or radiotherapy. In chapter 6 we 
described the first Dutch patient who was treated with vismodegib for a locally advanced BCC 
with locoregional metastasis of her BCC. An interesting detail is the presence of BCNS in this 
patient, already giving a preview of the effects of vismodegib on the multiple small BCCs in 
BCNS. Since the registration of the Hh pathway inhibitor vismodegib in the Netherlands in 
2014, it is possible to treat patients outside the clinical trial setting. However, it is important 
to realise that only very few patients with BCC are candidates for this systemic therapy. In 
2015 only 25 patients were treated for this indication in the Netherlands. Although treatment 
with Hh pathway inhibitors is initially effective, development of tumour resistance is common 
and adverse events frequently lead to discontinuation of therapy. Some patients with BCNS 
benefit from treatment with oral Hh pathway inhibitors, but especially in this group side effects 
are an important reason to discontinue therapy. An overview of treatment of BCC with Hh 
pathway inhibitors is given in chapter 7 and some aspects of this treatment are discussed in 
more detail below. We published the topics mentioned above in a national journal, as we believe 
it is important to share experiences on new treatment options.
Efficacy and side effects
Vismodegib is a small molecule inhibitor targeting the Hh pathway. Binding of vismodegib to 
SMO leads to inactivation of this pathway.26 Because most BCCs carry mutations in PTCH1 (the 
inhibitor of SMO) resulting in upregulation of the Hh pathway,25 vismodegib is initially effective 
in the vast majority of patients. The STEVIE trial assessed the safety and efficacy of vismodegib 
in patients with advanced BCC.27,28 In this trial 1215 patients (1119 laBCC, 96 mBCC) were 
treated with vismodegib with a mean follow-up of 18 months. The best measured response rate 
in patients with laBCC was a complete response in 33% and a partial response in 35%, stable 
disease in 25% and progressive disease in 2% of patients. The median duration of response 
was 23 months. In metastatic BCC the efficacy was lower. In only 5% of patients the best 
measured response was a complete response, in 32% a partial response, in 46% stable disease 
and progressive disease in 11%. The median duration of response was 12 months. At the clinical 
cut-off of the study, only 12% of patients were still receiving treatment with vismodegib. Main 
reasons to discontinue treatment were side effects and progressive disease. The presence of 
BCNS did not affect the efficacy of vismodegib.28 
127
10
Summary, discussion, future perspectives and valorisation
In general, 30 to 40% of patients discontinued therapy because of side effects.28 In patients 
treated because of BCNS-related multiple small BCCs even more than 50% could not continue 
therapy because of drug toxicity.29,30 Most frequently reported side effects, in about half of 
patients, are muscle cramps, dysgeusia and alopecia. Weight loss is reported in 33% of patients, 
possibly related with dysgeusia, but probably also due to changes in fat metabolism caused by the 
medication.28 Diarrhoea, nausea and fatigue are other common side effects. The development 
of cutaneous squamous cell carcinoma (SCC) during vismodegib therapy has been reported as 
well.31 The actual clinical impact of this observation is not clear, as later studies did not find a 
higher incidence of SCC during treatment.32 
Proper patient support and consultation of a dietician during treatment are essential to prevent 
weight loss. Intermittent treatment is already implemented in clinical practice to reduce toxicity. 
Unfortunately, studies on intermittent dosing regimens only show reduction in toxicity to a 
certain level.33
Drug resistance
A major problem in the treatment of BCC with vismodegib is the development of drug resistance. 
The majority of tumours initially show a complete or partial response to treatment with 
vismodegib. Only few BCCs do not respond at all, so called non-responders. The mean duration 
of response to therapy is 24 months.27 It is thought that about 15-20% of patients develop 
resistance, the exact percentage is unknown.27,43 The number of resistant cases is probably 
underestimated because of the short follow-up and the slow growth of BCC. In chapter 8 we 
describe two patients with locally advanced BCC, who are resistant to vismodegib. These cases 
illustrate how important it is to monitor the tumour area very carefully and perform sequential 
biopsies when needed. 
Genetically, BCC is one of the most heterogenic forms of cancer.25 However, for their growth 
BCCs are almost completely dependent on the Hh pathway. Genetic alterations that maintain Hh 
signalling in the presence of vismodegib are the primary mechanism of resistance. In chapter 9 
we describe a patient with acquired resistance to vismodegib due to SMO mutations. At the same 
time, it was found that drug resistance to vismodegib in the treatment of BCC is predominantly 
caused by SMO mutations that either directly impair drug binding or activate SMO to varying 
levels.35,36 The question is whether responsible mutations are acquired during treatment, or that 
they already existed before treatment. In the latter case, the minor clones may have benefited 
from a positive selection effect when other cells were killed by vismodegib. In the future, 
combination treatments should be developed to overcome or slow down the development of 
resistance. Drugs should inhibit SMO through different mechanisms or target the Hh pathway 
at points downstream of SMO. Several drug candidates are suggested in literature, for example 
itraconazol, bis-amides, arsenic oxide, protein-kinase inhibitors and mTOR inhibitors.37-40 There 
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are indications that imiquimod inhibits the Hh pathway as well.41 Furthermore, GLI-antagonists 
are very promising as they target the GLI transcription factors that are most downstream in the 
Hh pathway.42 Further research is needed to explore possible clinical applications of these drugs, 
especially in respect to pharmacokinetics and toxicity.
Hh inhibitors in basal cell naevus syndrome
Vismodegib has proven to be effective in the treatment of BCNS related BCCs. Existing BCCs 
disappear and development of new tumours is delayed.29,30 Unfortunately, discontinuation of 
treatment is common, mainly because of the side effects. Development of tumour resistance 
also occurs in patients with BCNS when it comes to laBCC or mBCC, but maybe to a more 
limited extent then in patients with sporadic BCC. Resistance is caused by the same underlying 
mechanism as in sporadic BCCs, as acquired SMO mutations are found in resistant tumour 
tissue.30 However, the BCNS-related small BCCs seem to develop resistance less frequently.30 
This is probably because small BCCs are less heterogenic then the large laBCCs.25 There is 
also evidence that syndromic BCCs have a lower mutational load and better genomic stability 
compared to sporadic BCCs, irrespective of the size of the tumour.43 Studies on intermittent 
treatment dosing regimens in patients with multiple BCCs show that interruption of treatment 
does not compromise activity of vismodegib, but only leads to some reduction in toxicity.33 
Optimal treatment regimens should be personalized and aim to strike a balance between 
sufficient activity and acceptable side effects as these patients need long-term treatment. At 
this moment vismodegib is not registered for treatment of multiple BCNS-related small BCCs. 
However, surgical treatment of the high number of BCCs may have unacceptable high morbidity 
in some patients. Radiotherapy is contraindicated in BCNS because of the induction of new 
tumours. Therefore, in selected patients with BCNS there is an indication for maintenance 
therapy with Hh pathway inhibitors.
Neoadjuvant therapy
One should be very cautious in using vismodegib as a neoadjuvant therapy in clinical practice. 
Treatment with vismodegib can cause discontinuous growth of the tumour, leading to an 
unreliable histological margin assessment.44 There is strong evidence that tumour cells remain 
present and become clinically manifest after treatment discontinuation.35,45 This means that 
to achieve a complete surgical resection the whole initially affected area should be removed 
anyway, so there is no benefit in reducing the tumour size before surgery. An interesting 
treatment option for non-syndromic locally advanced BCC is the combination of radiotherapy 
and vismodegib. This seems to be an effective and tolerable combination therapy, with a possible 
synergistic effect, but the results of a phase 2 trial are not yet available.46-48 
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Treatment settings and personalized medicine
A multidisciplinary oncological team in which a dermatologist, head and neck surgeon, 
oncological surgeon, radiotherapist, plastic surgeon and medical oncologist are represented, is 
the preferred setting for treatment of locally advanced BCC with Hh inhibitors.49 Only then all 
treatment options can be considered and experiences shared. Not only tumour characteristics 
are important in deciding which treatment is best for the patient, also patient characteristics 
are of great significance. The majority of skin cancer occurs in the elderly. In the ageing 
population, frailty is an important issue. The term frailty refers to a state of vulnerability to poor 
resolution of homoeostasis after a stressor event and is a consequence of cumulative decline 
in many physiological systems during a lifetime.50 In frail elderly, a minor stressor can trigger 
disproportionate changes in health status. In frail elderly with advanced BCC, surgery may be 
technically achievable, but associated with a high morbidity when complicated by for example 
delirium or hospital acquired pneumonia. Treatment with surgery or radiotherapy may lead to 
an impaired quality of life, for example when the BCC involves the orbita and treatment requires 
an enucleation or exenteration of the eye or leads to vision loss by radiation-induced toxicity. 
In those patients, palliative treatment with vismodegib may be an option, but it is important to 
realise that side effects, like muscle cramps and dysgeusia, can also significantly influence quality 
of life. Involvement of a geriatrist in making treatment decisions can be helpful in these cases.51 
Future perspectives on Hh pathway inhibitors for BCC
In the past decades, there has been a steep rise in the incidence of BCC. As BCC in general is 
a very slow growing tumour, it will take many years for it to become inoperable. As a logical 
consequence, the increase of neglected locally advanced tumours will lag many years behind the 
rise in incidence of BCC in general. As a direct result, in the nearby future an increasing number 
of patients with locally advanced or metastatic BCC that is ineligible for surgery or radiotherapy 
is to be expected. This emphasizes the need to optimize systemic treatment options for this 
group of patients. 
Rapid advancement in our understanding of Hh signalling in BCC has provided a new systemic 
treatment option for this common form of skin cancer: Hh pathway inhibitors. We already have 
insight into the mechanism of the development of resistance to Hh inhibitors in the treatment 
of BCC. In a next stage, treatment strategies to overcome the development of resistance need 
to be investigated. Combination therapy probably provides the best perspective. Different drug 
candidates are proposed in literature. However, development of combination therapy still has a 
long way to go before it can be used in clinical practice. 
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For the small BCNS related BCCs topical Hh inhibitors are a promising treatment option. The 
topical SMO inhibitor patidegib has been developed for this indication.52 Results from a phase 
II trial in which patients with BCNS are treated with patidegib have not yet been published. 
A multicentre phase 3 trial will start this year, with the MUMC as participating centre in the 
Netherlands.
The past years have seen many significant achievements in the field of cancer genetics, driven 
by rapidly evolving technologies and decreasing costs of next-generation sequencing (NGS). 
NGS is already used in clinical practice in several forms of cancer to predict responsiveness 
to therapy. The term ‘precision oncology’ was introduced, referring to the molecular profiling 
of tumours to identify targetable alterations and to predict response to therapies. Precision 
oncology simply means to give the right drugs to the right patients.19 In BCC, an NGS targeted 
panel consisting of genes participating in the Hh pathway allows us to analyse tumour tissue 
relatively cheaply and fast. With this technique, it is also possible to analyse paraffin embedded 
tissue. In the future, NGS will probably contribute to making treatment decisions for locally 
advanced or metastatic BCC.
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